Form 4 Oracle: Boston, MA -- Form4Oracle: Insider Trading Report: Enzo Biochem Inc (ENZ)

Jul 23, 2008 (M2 PRESSWIRE via COMTEX) -- ENZ | Quote | Chart | News | PowerRating -- at Enzo Biochem Inc (ENZ) has reported buying -- today.Over the last four weeks Rabbani Shahram K, Treasurer, Secretary has bought $1.10M increasing overall holdings by 4%.

For a current, real-time summary of ENZ insider activity, visit http://www.form4oracle.com/company?cik=0000316253&ticker=ENZ

About Form4Oracle

Form4Oracle, LLC specializes in distributing insider trading information published by the SEC, making it accessible and actionable for all types of investors. To learn more about how tracking insider trading activity can improve your investment returns, visit http://www.form4oracle.com.

About Enzo Biochem Inc

Enzo Biochem, Inc., a life sciences and biotechnology company, provides diagnostic services to the medical community. The company operates in three segments: Enzo Life Sciences, Enzo Therapeutics, and Enzo Clinical Labs. The Enzo Life Sciences segment manufactures, develops and markets biomedical research products and tools to research and pharmaceutical customers world wide. It offers products applied in the fields of gene expression, non-radioactive labeling and detection, adipokines and obesity, apoptosis, cell cycle, cytoskeletal research, DNA damage and repair, immunology and cancer research, inflammation, neurobiology, nitric oxide and oxidative stress, and signal transduction. The Enzo Therapeutics segment operates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Its therapeutic development programs include the HGTV43 gene medicine, which is in preclinical studies, for use in the treatment of human immunodeficiency virus; B27PD for the treatment of autoimmune uveitis; Alequel, which completed a phase II randomized double-blind clinical trial, for the treatment of treatment of Crohn's disease; EGS21 for the for treatment of fatty liver leading to non alcoholic steatohepatitis; Enzo-D58, which is in the preclinical development for the treatment of osteoporosis and certain bone disorders; and EHT899 immune regulation product, which completed preclinical animal studies, for the treatment of hepatitis B virus. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 19 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The company was founded in 1976 and is headquartered in New York, New York.

--------------------------------------------

The companies referenced in this report have not approved the statements made in this report. This report contains statements that imply risks and uncertainties. This material is for informational reporting purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Form4Oracle is not a licensed broker, broker dealer, market maker, investment banker, investment adviser, analyst or underwriter and is not compensated in this regard.

Please consult your broker to understand investing benefits and risks and prior to purchasing any securities mentioned herein.

CONTACT: Kimberly Sutton, Form4Oracle Tel: +1 312 315 5077 e-mail: kimberly@form4oracle.com WWW: http://www.form4oracle.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index